Background & Aims
Introduction
Colorectal cancer is a major global disease burden with about 1.4 million people diagnosed worldwide each year 1 and has a poor prognosis with 5-year survival rates below 60 % 1 . To reduce disease burden, many countries have introduced screening programmes for early detection and prevention of colorectal cancer.
One of the major concerns of cancer screening is interval cancers, cancers arising in the interval after a negative screening test. Interval cancers comprise three different groups: 1)
cancers arising from lesions missed at screening, 2) incompletely resected polyps, and 3) new lesions developing after screening. As endoscopy and removal techniques improve, the third group will likely be the largest 2, 3 . Cancers from this group are believed to be rapid-growing and more likely to metastasise and become lethal 4, 5 .
The concept of interval cancers is well known, but scarcely studied scientifically. Most studies on the prognosis of interval cancers concern breast cancer [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and many are hampered by lack of a valid control group [6] [7] [8] [9] [10] [11] [12] or short follow-up time 13 . Only a few existing studies on interval cancers apply a non-screened, age-matched population from the same time period with sufficiently long follow-up. These studies are limited to breast cancer screening [14] [15] [16] , prostate cancer screening 17 , and gFOBT (guaiac fecal occult blood test) screening 18 . A recent review of the evidence from molecular biology and from human studies of different cancer types, found no evidence supporting the theory that interval cancers are more lethal 19 . Similar findings have been observed in prostate-specific antigen (PSA) screening 17 .
Sigmoidoscopy screening has been shown to reduce colorectal cancer mortality and incidence, and endoscopic screening has been introduced in several countries in Europe the past few years 20 . While FOBT (fecal occult blood test) screening is offered every year or every second year, sigmoidoscopy screening is offered with longer time intervals between screening examinations (every 5 to 10 years or longer). Thus, the issue of interval cancer may be of greater importance. To our knowledge, there is a limited knowledge lack of data on the prognosis of interval cancer after sigmoidoscopy screening. As colorectal cancer screening becomes more widespread, optimal management of interval cancers will become an issue of increasing importance. Indeed, if they are more lethal than colorectal cancers in general, a more aggressive initial treatment might be justified, but the evidence for this is currently lacking.
We took advantage of a randomised controlled sigmoidoscopy screening trial, the Norwegian Colorectal Cancer Prevention (NORCCAP) trial, and compared colorectal cancer-specific and all-cause mortality of individuals with interval colorectal cancer to individuals diagnosed with colorectal cancer in a non-screened control group 21, 22 .
Methods

The NORCCAP trial
In the NORCCAP trial, all men and women aged 55-64 years living in the city of Oslo and
Telemark county, Norway, were identified through the Norwegian Population Registry in 1998, and randomised to sigmoidoscopy screening (with or without FOBT) or to a noscreening control group 21 . In 2000, the trial was extended to enrol all individuals aged 50-54 years in the same geographic areas. Due to higher birth rates in the latter group and a fixed screening capacity, the ratios between the screening and control group were 1:3 in the 55-64
years age group and 1:5.4 in the 50-54 years age group. When combining the two age groups, the mean age in the screening group was slightly higher than in the control group (56.9 vs 56.1 years). Thus, in the present study, all survival and multivariate analyses are ageadjusted 21 .
All screening examinations were performed at three dedicated centres between 1999 and 2001. During sigmoidoscopy, all detected lesions were biopsied and subjected to histopathological evaluation. Advanced adenomas were defined as having high-grade dysplasia, a size of 10 mm or more, or a villous component. Individuals randomised to sigmoidoscopy and FOBT screening brought a fecal sample to the screening centre on the day of screening. All individuals with a positive screen -defined as a polyp of 10 mm or larger, any adenoma, colorectal cancer, or a positive FOBT -were referred for colonoscopy.
Colonoscopies were performed at the screening centres within 6 weeks after screening.
During colonoscopy, all lesions were removed 21 . All screening participants received a written screening report with findings and performed therapy, recommended surveillance if any, and statement on regardless of the screening, they should see their doctor and request a colonoscopy if symptoms occur in the future, with a copy to the patient's primary care physician to be retained in the patient file.
During the course of the trial and the follow-up period, there was no recommendation for colorectal cancer screening in Norway and no access to colorectal cancer screening for the population outside of the trial 23 .
All NORCCAP participants who attended the screening intervention provided written informed consent. The Ethics Committee of South-East Norway and the Norwegian Data Protection Authority approved the NORCCAP study.
Design and Participants
All participants in the NORCCAP trial were followed through linkage to national Norwegian registries for cancer and cause-specific death, using the Norwegian unique personal identification number. Date of colorectal cancer diagnosis was obtained from the Cancer
Registry of Norway, date and cause of death was obtained from the Norwegian Cause of Death Registry, and date of emigration from Statistics Norway. These registries are close to 100 % complete 24 .
In the present study, we included all individuals in the NORCCAP trial diagnosed with colorectal cancer during a median 14.8 years of follow-up. From the screening group, we excluded screening non-compliers and those who were diagnosed with colorectal cancer at screening or within 30 days after the last examination (including clearing colonoscopies that were part of the screening intervention) ( Figure 1 ). We also excluded individuals who were first diagnosed with colorectal cancer at autopsy. Colorectal cancer was defined as adenocarcinoma of the colon or the rectum (ICD-10 codes C18-C20). Rectosigmoid cancer was defined as adenocarcinoma distal to the descending-sigmoid junction (ICD-10 codes C18.9, C19.9, C20.9). Tumours were staged according to Dukes' classification 25 .
Individuals were included at the date of colorectal cancer diagnosis, and followed until the date of death, emigration, or end of follow-up on December 31st 2015, whichever occurred first. We compared colorectal cancer-specific and all-cause mortality in the following two groups ( Figure 1 
Statistics
The baseline characteristics were compared with the student's t-test or chi-square test, as appropriate. We used univariable Cox regression analyses to compare colorectal cancerspecific and all-cause mortality in the two study groups. We fitted a multivariable Cox regression model including the variables patient age and sex. We did separate analyses including only patients with cancer in the rectosigmoid since this was the reach of the screening tool. We performed a sensitivity analysis including only patients diagnosed with colorectal cancer within the first 10 years after study entry. In a separate sensitivity analysis we censored individuals after 10, 5 and 2.5 years of follow-up (the median follow-up in the interval cancer group) to evaluate the possible impact of lead-time bias due to differential colonoscopy activity in the two groups during follow-up.
As a measure of absolute difference between the study groups, we compared the colorectal cancer mortality rate. To adjust for differences in age at diagnosis and sex between the groups, we used stabilised inverse probability weights (IPW) 26 , calculated as the probability of being in the interval cancer group divided by the probability of being in the interval cancer group adjusted for age and sex. We used bootstrap to estimate 95 % confidence intervals for the difference in absolute rates. Survival is displayed as IPW-adjusted Kaplan-Meier curves 27 .
We also present age-adjusted curves for the hazard functions of colorectal cancer mortality for the first five years after diagnosis, calculated as a weighted kernel-density estimate using the estimated hazard contributions. Statistical tests were two-sided, and P-values < 0.05 were considered statistically significant. We used Stata version 14.1 (StataCorp LP, Texas, USA) for analyses.
Results
A total of 98,678 individuals were randomised and included in the NORCCAP trial: 20, 552 in the screening arm and 78,126 in the control arm ( Figure 1 ). All individuals were followed At screening, 31 of 163 individuals in the interval cancer group had adenomas removed, 14 of which were high-risk (Appendix Table 1 ). All 31 patients had at least one colonoscopy with caecal intubation at baseline. Altogether 17 individuals were recommended surveillance colonoscopy, and one was diagnosed with colorectal cancer at a surveillance colonoscopy.
The median time from study enrollment to cancer diagnosis is slightly longer in the interval cancer group as compared to the control group (10.5 years versus 9.9 years; P=.14). Figure 2A , Figure 2B , Appendix Figure 1 ). There was no significant difference in individuals who were screening positive and those who were screening negative (adjusted HR, 0.87; 95% CI, 0.40-1.89; P=.72).
Results were similar for women (age-adjusted HR, 1.00; 95% CI, 0.65-1.57; P=.97) and for men (age-adjusted HR, 0.98; 95% CI, 0.63-1.53; P=.94) (Appendix Figure 2) . Sensitivity analyses including only individuals diagnosed within 10 years after screening or excluding the one colorectal cancer diagnosed at surveillance did not alter the results, neither did censoring of follow-up at 10, 5 and 2.5 years after colorectal cancer diagnosis (Appendix Table 2 ).
The age-and sex-adjusted colorectal cancer-specific mortality rate per 1,000 person-years was 67.0 in the interval cancer group and 74.8 in the control group, corresponding to 7. All-cause mortality did not differ significantly in the two groups (adjusted HR, 0.99; 95% CI, 0.76-1.27; P=.91) ( Figure 2C ).
Rectosigmoid cancer
A lower proportion of colorectal cancers were located distal to the descending-sigmoid junction in the interval cancer group (30.1%) compared to the control group (57.2%) ( Table   1) .
Altogether, 1,045 individuals were diagnosed with rectosigmoid cancer, and 290 individuals died of rectosigmoid cancer (13 in the interval cancer group and 277 in the control group). In multivariable regression analyses, we found no difference between the interval cancer group and the control group (adjusted HR, 1.10; 95% CI, 0.63-1.92; P=.74) ( Figure 2D ).
Censoring the follow-up after rectosigmoid cancer diagnosis at 10, 5 and 2.5 years, did not change the results (Appendix Table 3 ).
Women had less interval cancers in the rectosigmoid colon (21.1%) compared to men (41.1%) (Appendix Table 4 ). There was no difference in rectosigmoid cancer mortality in the interval cancer group compared to the control group in neither women (adjusted HR, 1.62; 95% CI, 0.71-3.70), nor men (adjusted HR, 0.86; 95% CI, 0.41-1.84). There was no significant difference between women and men (P=.28).
Discussion
Our findings show that individuals with interval cancers after sigmoidoscopy screening have similar prognosis compared to individuals with clinically detected colorectal cancer.
One could argue that sigmoidoscopy only visualizes the distal colon and thus, only distal CRC should be counted for estimation of interval cancers. However, sigmoidoscopy screening is a screening test for colorectal cancer in general, not only for distal colorectal cancer, as recommended by CRC screening guidelines. While sigmoidoscopy screening visualises and removes adenomas of the rectosigmoid colon only, it may also identify those at high risk of proximal lesions, which is the rationale for colonoscopy follow-up for those with screen-detected pathology in the distal colon. Like in FOBT screening, sigmoidoscopy screening is a package, where positive individuals are followed-up by colonoscopy. Also
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FOBT screening has higher sensitivities for distal cancers, but like in our primary analysis, studies of interval cancers in FOBT screening do include all CRCs. We therefore in our primary analysis defined cancers occurring after the screening procedure as interval cancers regardless of whether the cancer was located within the reach of the sigmoidoscope or not, but also performed an analysis restricted to distal cancers. Reassuringly, we found that colorectal cancer-specific and all-cause mortality were similar in the interval cancer and control group, regardless of whether definition on interval cancer was all colorectal cancers or restricted to rectosigmoid cancers only.
Previously, it has been shown that interval cancers in mammography screening 15, 16 , gFOBT screening 18 , and PSA screening 17 Another difference between the tests mentioned above is their varying sensitivities: the sensitivity of mammography has been reported to vary between 75.5-92.1% 28, 29 , gFOBT between 24-92% [30] [31] [32] [33] , PSA between 33-59% 34 . The low sensitivity may dilute the interval cancer group with slow-growing cancers missed at screening, so that interval cancers may appear to have similar prognosis as clinically detected cancers in a non-screened population.
However, as long as these are the available screening methods and we cannot distinguish between true and missed interval cancers, the distinction has no clinical impact. Thus, together with the results of this study on sigmoidoscopy screening and colorectal cancer, there is no indication overall that the mortality of interval cancers in general is worse than that of non-screened clinically detected cancers.
It has recently been shown that sigmoidoscopy screening may be more beneficial for men than for women 22, 35 . In addition, women have a higher proportion of proximal cancers than men 18, 36, 37 . It is therefore discussed whether colonoscopy rather than sigmoidoscopy, might be the preferred screening method for women. In this study, we found that women had a higher proportion of proximal compared to rectosigmoid interval cancers than men. However, there was a tendency that women had a higher risk of dying from rectosigmoid interval M A N U S C R I P T
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cancer than men. This suggests poor effectiveness of screening in women. However, our analysis is under-powered and this finding may be due to chance.
The interval cancer group comprise individuals complying with a screening programme.
However, as the control group in the present study is neither informed nor given a choice to participate, the group consists of individuals who would, if given a choice, be either compliers or non-compliers with the screening programme. People who choose to comply with a screening programme may be more healthy 21 , more motivated to treatment when disease occurs, and more prone to seek health care when experiencing symptoms. On the other hand, the group undergoing screening may feel safe from disease after a negative screening, and thus seek health care later when symptoms occur 38 . In addition, slow-growing cancers are detected at screening and removed from the interval cancer group, in contrast to the control group, which consists of both slow-and fast-growing cancers. It is not possible to control for these possible biases. However, as all-cause mortality was similar in the interval cancer and the control groups, biases are unlikely. If there were substantial selection bias, we would expect the interval cancer group to have lower all-cause mortality. Further, since we compared the interval cancer group with a non-screened control group within a randomised controlled trial, we have a most valid comparison group, similar to the general population.
Interval cancers are the cancers that were not detected at screening and were not prevented due to polypectomy. The same category of cancers will occur in the control group, but there they are not possible to identify since no screening is offered in the control group. One may argue that including "interval cancers" in the control-group dilutes a possible difference between interval cancers and the control-group. However, this comparison is the one valid comparison as all cancers are detected clinically, any other comparison would not be valid due to selection biases.
Screen-detected colorectal cancers were not included in the analyses, as they will affect our results due to lead-time (i.e. the diagnosis is made earlier due to screening than it would be without screening) and make survival look better for screen-detected cancers compared to the control group. Only one cancer was found at surveillance (0.6% of interval cancers), and may thus be prone to lead-time bias. However, in a sensitivity analysis excluding this patient we found similar results as in the main analyses.
This study shows that both colorectal cancer-specific and all-cause mortality of interval cancer after a normal sigmoidoscopy screen is similar to that of a clinically detected cancer in M A N U S C R I P T
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